Europe Pen Needles Market Report

Europe Pen Needles Market Size

The pen needles market size in Europe is projected to grow from USD 0.89 billion in 2024 to USD 2.11 billion by 2033, at a CAGR of 10.04%.

Needle manufacturers have produced needles to reduce pain and diminish skin trauma, primarily by innovating needle length and diameter. The primary challenge for needle manufacturers is to keep a sufficient inner lumen while maintaining a sufficiently low injection force. Pen needles are used to administer medication, such as insulin or other injectable medicines, combined with injection pens. A pen needle contains a hollow needle connected to an injection pen. Pen needles are prepared with various needle lengths and used by diabetes patients.

The growing rate of diabetic patients, the existence of favorable regulatory policies to reduce needlestick injuries, the growing focus on the utilization of safety equipment by the government, increasing funds for diabetes care & research in the U.K., and favorable reimbursement policies in Germany are accelerating the growth of the pen needle market in Europe. Additionally, an increasingly aging population & availability of high insurance in France, a growing number of diabetes awareness programs in Italy, and the existence of regulations that mandate the utilization of safety pen needles & the presence of a substantial diabetic population in Spain are further driving the growth of the market in Europe.

The reusability of pen needles, complications associated with needle use, and availability of alternative dosage forms may hamper the region's market growth. Lack of knowledge among people on pen needle utilization and uncertain reimbursement policies across Europe are restraining the development of the pen needle market in Europe.

REGIONAL ANALYSIS

In this region, Germany is estimated to account for the largest share of the Europe pen needles market in 2023. In contrast, France is estimated to grow at the highest CAGR during the forecast period. Europe is expected to see an overall boost in the pen needle market due to the rising prevalence of its target disease. Moreover, the U.K. government is also taking initiatives to invest in diabetes care and research to improve diabetic patients' treatment techniques. Europe is projected to dominate the global market due to a rise in the prevalence of diabetes among all ages, technological advancements, and an increase in research and development activities on diabetes care. This dominance may also be due to a rise in overweight & obesity, unhealthy diet, and physical inactivity.

KEY MARKET PLAYERS

Companies that play a promising role in the Europe pen needles market include Becton Dickinson and Company, Novo Nordisk A/S, Ypsomed Holding AG, UltiMed, Inc., Allison Medical, Inc., Owen Mumford, Ltd., B. Braun Melsungen, Artsana S.p.a., HTL-STREFA S.A., and Terumo Corporation.

RECENT MARKET HAPPENINGS

• In February 2019, Bigfoot Biomedical, Inc. and Owen Mumford Ltd. announced a supply to assist with the pen needles in Bigfoot's subscription supply bundles. This contract will confirm that the customers continuously have access to a contented and high-quality pen needle for every insulin dose. It would also help evolve a digital drug delivery platform projected for sustained insulin delivery to all people with insulin-requiring diabetes.
• In 2018, Becton, Dickinson, and Company (U.S.) launched its BD Ultra-Fine micro pen needle 6mm x 32G.

MARKET SEGMENTATION

This research report on the European pen needles market has been segmented and sub-segmented based on therapy, type, needle length, mode of purchase, and country.

By Therapy

• Insulin Therapy
• GLP-1 Therapy
• Growth Hormone Therapy

By Type

• Standard Needle
• Safety Needle

By Needle Length

• 4mm
• 6mm
• 8mm
• 10mm
• 12mm

By Mode of Purchase

• Retail
• Non-Retail

By Country

• The UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe